Dekavil
Phase 1
PfizerDekavil is one of 32 therapeutic programs targeting Rheumatoid Arthritis. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Enbrel
IImmunex
Preclinical
Arcoxia
NovartisPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Cataflam
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Dekavil. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company